PDF(Pubmed)
Abstract：
BACKGROUND: Diabetes and thyroiditis are closely related. They occur in combination and cause significant damage to the body. There is no clear treatment for type-2 diabetes mellitus (T2DM) with Hashimoto\'s thyroiditis (HT). While single symptomatic drug treatment of the two diseases is less effective, combined drug treatment may improve efficacy.
OBJECTIVE: To investigate the effect of a combination of vitamin D, selenium, and hypo-glycemic agents in T2DM with HT.
METHODS: This retrospective study included 150 patients with T2DM and HT treated at The Central Hospital of Shaoyang from March 2020 to February 2023. Fifty patients were assigned to the control group, test group A, and test group B according to different treatment methods. The control group received low-iodine diet guidance and hypoglycemic drug treatment. Test group A received the control treatment plus vitamin D treatment. Test group B received the group A treatment plus selenium. Blood levels of markers of thyroid function [free T3 (FT3), thyroid stimulating hormone (TSH), free T4 (FT4)], autoantibodies [thyroid peroxidase antibody (TPOAB) and thyroid globulin antibody (TGAB)], blood lipid index [low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triacylglycerol (TG)], blood glucose index [fasting blood glucose (FBG), and hemoglobin A1c (HbA1c)] were measured pre-treatment and 3 and 6 months after treatment. The relationships between serum 25-hydroxyvitamin D3 [25 (OH) D3] level and each of these indices were analyzed.
RESULTS: The levels of 25 (OH) D3, FT3, FT4, and LDL-C increased in the order of the control group, test group A, and test group B (all P < 0.05). The TPOAB, TGAB, TC, TG, FBG, HbA1c, and TSH levels increased in the order of test groups B, A, and the control group (all P < 0.05). All the above indices were compared after 3 and 6 months of treatment. Pre-treatment, there was no divergence in serum 25 (OH) D3 level, thyroid function-related indexes, autoantibodies level, blood glucose, and blood lipid index between the control group, test groups A and B (all P > 0.05). The 25 (OH) D3 levels in test groups A and B were negatively correlated with FT4 and TGAB (all P < 0.05).
CONCLUSIONS: The combination drug treatment for T2DM with HT significantly improved thyroid function, autoantibody, and blood glucose and lipid levels.
OBJECTIVE: To investigate the effect of a combination of vitamin D, selenium, and hypo-glycemic agents in T2DM with HT.
METHODS: This retrospective study included 150 patients with T2DM and HT treated at The Central Hospital of Shaoyang from March 2020 to February 2023. Fifty patients were assigned to the control group, test group A, and test group B according to different treatment methods. The control group received low-iodine diet guidance and hypoglycemic drug treatment. Test group A received the control treatment plus vitamin D treatment. Test group B received the group A treatment plus selenium. Blood levels of markers of thyroid function [free T3 (FT3), thyroid stimulating hormone (TSH), free T4 (FT4)], autoantibodies [thyroid peroxidase antibody (TPOAB) and thyroid globulin antibody (TGAB)], blood lipid index [low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triacylglycerol (TG)], blood glucose index [fasting blood glucose (FBG), and hemoglobin A1c (HbA1c)] were measured pre-treatment and 3 and 6 months after treatment. The relationships between serum 25-hydroxyvitamin D3 [25 (OH) D3] level and each of these indices were analyzed.
RESULTS: The levels of 25 (OH) D3, FT3, FT4, and LDL-C increased in the order of the control group, test group A, and test group B (all P < 0.05). The TPOAB, TGAB, TC, TG, FBG, HbA1c, and TSH levels increased in the order of test groups B, A, and the control group (all P < 0.05). All the above indices were compared after 3 and 6 months of treatment. Pre-treatment, there was no divergence in serum 25 (OH) D3 level, thyroid function-related indexes, autoantibodies level, blood glucose, and blood lipid index between the control group, test groups A and B (all P > 0.05). The 25 (OH) D3 levels in test groups A and B were negatively correlated with FT4 and TGAB (all P < 0.05).
CONCLUSIONS: The combination drug treatment for T2DM with HT significantly improved thyroid function, autoantibody, and blood glucose and lipid levels.
摘要：
背景：糖尿病和甲状腺炎密切相关。它们组合发生并对身体造成重大损害。2型糖尿病（T2DM）合并桥本甲状腺炎（HT）尚无明确的治疗方法。而两种疾病的单一对症药物治疗效果较差，联合药物治疗可提高疗效。
目的：为了研究维生素D组合的效果，硒,2型糖尿病合并HT的降血糖药。
方法：这项回顾性研究包括2020年3月至2023年2月在邵阳市中心医院接受治疗的150例T2DM和HT患者。50名患者被分配到对照组，试验组A,试验B组按治疗方法不同。对照组给予低碘饮食指导和降糖药物治疗。试验组A接受对照治疗加维生素D治疗。试验B组接受A组治疗加硒。甲状腺功能标志物的血液水平[游离T3（FT3），促甲状腺激素(TSH),自由T4(FT4)],自身抗体[甲状腺过氧化物酶抗体（TPOAB）和甲状腺球蛋白抗体（TGAB）]，血脂指标[低密度脂蛋白胆固醇（LDL-C），总胆固醇(TC),三酰甘油（TG）]，血糖指数[空腹血糖（FBG），治疗前和治疗后3个月和6个月测量血红蛋白A1c（HbA1c）]。分析血清25-羟基维生素D3[25（OH）D3]水平与这些指标之间的关系。
结果：25（OH）D3，FT3，FT4和LDL-C的水平按对照组的顺序增加，试验组A,试验B组(均P<0.05)。TPOAB,TGAB,TC,TG,FBG,HbA1c,TSH水平按试验组B的顺序增加，A,对照组(均P<0.05)。治疗3、6个月后比较上述指标。预处理,血清25（OH）D3水平没有差异，甲状腺功能相关指标，自身抗体水平，血糖，与对照组之间的血脂指标,试验A、B组(P均>0.05)。试验A、B组25(OH)D3水平与FT4、TGAB呈负相关(均P<0.05)。
结论：联合用药可明显改善T2DM合并HT患者的甲状腺功能，自身抗体,血糖和血脂水平。
目的：为了研究维生素D组合的效果，硒,2型糖尿病合并HT的降血糖药。
方法：这项回顾性研究包括2020年3月至2023年2月在邵阳市中心医院接受治疗的150例T2DM和HT患者。50名患者被分配到对照组，试验组A,试验B组按治疗方法不同。对照组给予低碘饮食指导和降糖药物治疗。试验组A接受对照治疗加维生素D治疗。试验B组接受A组治疗加硒。甲状腺功能标志物的血液水平[游离T3（FT3），促甲状腺激素(TSH),自由T4(FT4)],自身抗体[甲状腺过氧化物酶抗体（TPOAB）和甲状腺球蛋白抗体（TGAB）]，血脂指标[低密度脂蛋白胆固醇（LDL-C），总胆固醇(TC),三酰甘油（TG）]，血糖指数[空腹血糖（FBG），治疗前和治疗后3个月和6个月测量血红蛋白A1c（HbA1c）]。分析血清25-羟基维生素D3[25（OH）D3]水平与这些指标之间的关系。
结果：25（OH）D3，FT3，FT4和LDL-C的水平按对照组的顺序增加，试验组A,试验B组(均P<0.05)。TPOAB,TGAB,TC,TG,FBG,HbA1c,TSH水平按试验组B的顺序增加，A,对照组(均P<0.05)。治疗3、6个月后比较上述指标。预处理,血清25（OH）D3水平没有差异，甲状腺功能相关指标，自身抗体水平，血糖，与对照组之间的血脂指标,试验A、B组(P均>0.05)。试验A、B组25(OH)D3水平与FT4、TGAB呈负相关(均P<0.05)。
结论：联合用药可明显改善T2DM合并HT患者的甲状腺功能，自身抗体,血糖和血脂水平。
